(PharmaNewsWire.Com, June 10, 2021 ) According to research report Autotransfusion Market is projected to reach USD 505 million by 2024 from USD 395 million in 2019 at a CAGR of 5.0%.
The growth of the autotransfusion devices market is driven by the increasing number of surgical procedures, rising number of transplant procedures, advantages of autotransfusion, and scarcity of donated blood/allogenic blood.
Autotransfusion products, by type, accounted for the largest share of the autotransfusion systems market, in 2019.
On the basis of type, the autotransfusion devices market is segmented into autotransfusion products & accessories. The autotransfusion products segment accounted for the largest share of the autotransfusion systems market in 2019.
Autotransfusion products are associated with a number of advantages, which are expected to boost its adoption in the coming years. These components prevent the transmission of transfusion-related blood-borne diseases in patients, and they also provide more compatible blood in comparison to autologous blood transfusions. These advantages are likely to increase the demand for autotransfusion products during the forecast period.
The cardiac surgeries segment, by application, is expected to register the highest growth rate in the autotransfusion devices market during the forecast period in 2019.
On the basis of application, the autotransfusion market is segmented into Cardiac Surgeries, Orthopedic Surgeries, Organ Transplantation, Trauma Procedures, and Other Procedures. The cardiac surgeries segment is expected to register the highest growth rate due to the high prevalence of cardiac diseases and recommendations for autologous transfusion (by entities such as the WHO) during cardiac surgeries.
Becton, Dickinson and Company (US), Zimmer Biomet Holdings, Inc. (US), Teleflex Incorporated (US), and Haemonetics Corporation (US) are some of the major players operating in the North American autotransfusion market.
North America, by region, held the largest share of the autotransfusion market in 2019.
The large share of the North American market can mainly be attributed to the high and growing prevalence of target health conditions (cardiovascular, orthopedic, and trauma cases), increasing number of major transplant procedures, scarcity of allogenic blood, preference for autologous blood (due to its advantages), and the strong presence of key market players in the region.
Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 sales@marketsandmarkets.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
